Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 56.83
- Piotroski Score 3.00
- Grade Buy
- Symbol (SMMT)
- Company Summit Therapeutics Inc.
- Price $21.90
- Changes Percentage (4.86%)
- Change $1.02
- Day Low $20.25
- Day High $22.05
- Year High $33.89
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $45.00
- Low Stock Price Target $23.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.38
- Trailing P/E Ratio 20.32
- Forward P/E Ratio 20.32
- P/E Growth 20.32
- Net Income $-614,928,000
Income Statement
Quarterly
Annual
Latest News of SMMT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024?
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks as the best performing stock in 2024. The company focuses on developing innovative oncology treatments, with successful Phase 3 trials and collaborations. ...
By Yahoo! Finance | 4 days ago -
Car production down by more than 14% in July, says SMMT
Car production dropped over 14% last month, with 65,478 vehicles made in July. Major export markets were the EU, US, China, Turkey, and Japan....
By Yahoo! Finance | 1 month ago -
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History
Summit Therapeutics Inc. is a biopharmaceutical company in the US and UK, focusing on developing patient-friendly therapies. Their lead candidate is Ivonescimab, a bispecific antibody for immunotherap...
By Yahoo! Finance | 2 months ago